1932

Abstract

The theme “New Approaches for Studying Drug and Toxicant Action: Applications to Drug Discovery and Development” links 13 articles in this volume of the (). The engaging prefatory articles by Arthur Cho and Robert Lefkowitz set the stage for this theme and for the reviews that insightfully describe new approaches that advance research and discovery in pharmacology and toxicology. Examples include the progress being made in developing Organs-on-Chips/microphysiological systems and human induced pluripotent stem cell–derived cells to aid in understanding cell and tissue pharmacokinetics, action, and toxicity; the recognition of the importance of circadian rhythm, the microbiome, and epigenetics in drug and toxicant responses; and the application of results from new types of patient-derived information to create personalized/precision medicine, including therapeutics for pain, which may perhaps provide help in dealing with the opioid epidemic in the United States. Such new information energizes discovery efforts in pharmacology and toxicology that seek to improve the efficacy and safety of drugs in patients and to minimize the consequences of exposure to toxins.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-092617-121952
2018-01-06
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/pharmtox/58/1/annurev-pharmtox-092617-121952.html?itemId=/content/journals/10.1146/annurev-pharmtox-092617-121952&mimeType=html&fmt=ahah

Literature Cited

  1. Cho AK. 1.  2018. A chemical perspective of pharmacology and toxicology. Annu. Rev. Pharmacol. Toxicol 58:1–16 [Google Scholar]
  2. Lefkowitz RJ. 2.  2018. A serendipitous scientist. Annu. Rev. Pharmacol. Toxicol 58:17–32 [Google Scholar]
  3. Snyder SH. 3.  2017. A life of neurotransmitters. Annu. Rev. Pharmacol. Toxicol. 57:1–11 [Google Scholar]
  4. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP. 4.  et al. 2014. International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol. Rev. 66:918–47 [Google Scholar]
  5. Changeux JP, Christopoulos A. 5.  2016. Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166:1084–102 [Google Scholar]
  6. Prantil-Baun R, Novak R, Das D, Somayaji MR, Przekwas A, Ingber DE. 6.  2018.. Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked Organs-on-Chips. Annu. Rev. Pharmacol. Toxicol. 58:37–64 [Google Scholar]
  7. Ewart L, Dehne EM, Fabre K, Gibbs S, Hickman J. 7.  et al. 2018. Application of microphysiological systems to enhance safety assessment in drug discovery. Annu. Rev. Pharmacol. Toxicol 58:65–82 [Google Scholar]
  8. Magdy T, Schuldt AJT, Wu JC, Bernstein D, Burridge PW. 8.  2018. Human induced pluripotent stem cell (hiPSC)-derived cells to assess drug cardiotoxicity: opportunities and problems. Annu. Rev. Pharmacol. Toxicol 58:83–103 [Google Scholar]
  9. Peck RW. 9.  2018. Precision medicine is not just genomics: the right dose for every patient. Annu. Rev. Pharmacol. Toxicol 58:105–22 [Google Scholar]
  10. Sexton JE, Cox JJ, Zhao J, Wood JN. 10.  2018. The genetics of pain: implications for therapeutics. Annu. Rev. Pharmacol. Toxicol 58:123–42 [Google Scholar]
  11. Skolnick P. 11.  2018. The opioid epidemic: crisis and solutions. Annu. Rev. Pharmacol. Toxicol 58:143–59 [Google Scholar]
  12. Lauschke VM, Barragan I, Ingelman-Sundberg M. 12.  2018. Pharmacoepigenetics and toxicoepigenetics: novel mechanistic insights and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol 58:161–85 [Google Scholar]
  13. Bennett RL, Licht JD. 13.  2018. Targeting epigenetics in cancer. Annu. Rev. Pharmacol. Toxicol 58:187–207 [Google Scholar]
  14. Angus SP, Zawistowski JS, Johnson GL. 14.  2018. Epigenetic mechanisms regulating adaptive responses to targeted kinase inhibitors in cancer. Annu. Rev. Pharmacol. Toxicol 58:209–29 [Google Scholar]
  15. Chen Z, Yoo SH, Takahashi JG. 15.  2018. Development and therapeutic potential of small-molecule modulators of circadian systems. Annu. Rev. Pharmacol. Toxicol 58:231–52 [Google Scholar]
  16. Paschos GK, Baggs JE, Hogenesch JB, FitzGerald GA. 16.  2010. The role of clock genes in pharmacology. Annu. Rev. Pharmacol. Toxicol. 50:187–214 [Google Scholar]
  17. Dallmann R, Brown SA, Gachon F. 17.  2014. Chronopharmacology: new insights and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 54:339–61 [Google Scholar]
  18. Vázquez-Baeza Y, Callewaert C, Debelius JW, Hyde ER, Marotz C. 18.  et al. 2018. Impacts of the human gut microbiome on therapeutics. Annu. Rev. Pharmacol. Toxicol 58:253–70 [Google Scholar]
/content/journals/10.1146/annurev-pharmtox-092617-121952
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error